Biotrans ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.3% 1.3% 1.3% 1.3% 1.3%  
Bankruptcy risk  6.9% 5.7% 7.9% 3.4% 3.1%  
Credit score (0-100)  35 39 30 53 56  
Credit rating  BBB BBB BB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  4,695 4,776 6,385 7,326 7,969  
EBITDA  995 1,010 1,367 1,194 2,643  
EBIT  582 575 833 783 2,035  
Pre-tax profit (PTP)  556.6 573.1 745.4 545.9 1,900.5  
Net earnings  426.0 441.3 560.2 413.7 1,458.8  
Pre-tax profit without non-rec. items  557 573 745 546 1,901  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  259 391 1,317 1,601 1,712  
Shareholders equity total  890 1,011 1,222 1,385 2,569  
Interest-bearing liabilities  353 166 993 1,085 252  
Balance sheet total (assets)  7,462 7,371 7,757 6,903 8,153  

Net Debt  -807 -1,925 960 999 -936  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  4,695 4,776 6,385 7,326 7,969  
Gross profit growth  61.9% 1.7% 33.7% 14.7% 8.8%  
Employees  8 8 10 12 10  
Employee growth %  14.3% 0.0% 25.0% 20.0% -16.7%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  7,462 7,371 7,757 6,903 8,153  
Balance sheet change%  52.7% -1.2% 5.2% -11.0% 18.1%  
Added value  994.6 1,009.7 1,366.9 1,316.2 2,642.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -460 -591 -64 57 -234  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  12.4% 12.0% 13.1% 10.7% 25.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  9.9% 8.2% 11.0% 10.7% 27.1%  
ROI %  51.7% 56.2% 45.5% 27.5% 63.4%  
ROE %  62.9% 46.4% 50.2% 31.7% 73.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  11.9% 13.7% 15.8% 20.1% 32.4%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -81.2% -190.7% 70.2% 83.7% -35.4%  
Gearing %  39.6% 16.4% 81.3% 78.3% 9.8%  
Net interest  0 0 0 0 0  
Financing costs %  11.1% 14.6% 15.2% 23.3% 20.3%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.9 1.0 0.8 0.8 1.0  
Current Ratio  1.0 1.1 1.1 1.1 1.2  
Cash and cash equivalent  1,160.1 2,091.1 33.6 86.3 1,188.2  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  240.8 485.3 542.0 286.0 1,130.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  124 126 137 110 264  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  124 126 137 100 264  
EBIT / employee  73 72 83 65 204  
Net earnings / employee  53 55 56 34 146